Colorectal News and Research

RSS

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.

8 Oct 2009

Panel Intelligence expands patient focused market research service

Panel Intelligence, LLC, is pleased to announce expanded capabilities for patient focused market research. For 10 years, Panel Intelligence has provided actionable market intelligence in the form of primary research from clinicians and other healthcare professionals.

7 Oct 2009

New tool to help reduce cost and time factors for colonoscopies

Colorectal cancer is a leading cause of cancer-related deaths in the United States, leading to over 50,000 fatalities every year. But it can be prevented with early screening using a procedure called a colonoscopy. Now researchers from North Carolina State University, Mayo Clinic and the University of Massachusetts at Amherst (UMass) have created a tool to help colonoscopy facilities operate more efficiently, ultimately lowering costs and leading to shorter waiting times for patients.

7 Oct 2009

Clinical Genomics extends collaboration with CSIRO

Sydney-based Clinical Genomics Pty Ltd and CSIRO have entered into a new phase in their collaboration to develop improved diagnostics for cancers of the colon and rectum (bowel cancer).

7 Oct 2009

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.

7 Oct 2009

Fred Hutchinson Cancer Research Center receives 60 research grants totaling nearly $40.4 million

Scientists at Fred Hutchinson Cancer Research Center have been awarded 60 research grants totaling nearly $40.4 million under the American Recovery & Reinvestment Act of 2009. The totals reflect data available as of Oct. 1 and reported by the National Institutes of Health.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

Group Health Research Institute to receive federal stimulus funds from ARRA

Group Health Research Institute, formerly Group Health Center for Health Studies, will receive more than $15 million in federal stimulus funding from ARRA, the American Recovery and Reinvestment Act of 2009.

6 Oct 2009

$16 million federal stimulus funds for cancer research projects

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

6 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

UnitedHealthcare launches 2010 portfolio of Medicare products

UnitedHealthcare, a UnitedHealth Group company, today introduced its 2010 portfolio of Medicare products that provide seniors an affordable way to manage their health care and prescription drug needs.

5 Oct 2009

Diagnocure signs agreement with Lab21 for marketing its Previstage test

DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.

5 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

New strategic research service for the oncology market launched by Health Strategies Group

Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has just launched Oncology Performance Edge, a new strategic research service that helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources.

3 Oct 2009

Screening and diagnostic tests contribute to health care value across spectrum of care

Amidst ongoing debate in Congress over reforming the nation's health care system, a new report from the Lewin Group finds that screening and diagnostic laboratory tests are central to achieving some of the most important goals of health care reform.

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.

1 Oct 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Younger women with metastatic colorectal cancer live longer than younger men

Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

30 Sep 2009

Colorectal News and Research

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

Panel Intelligence expands patient focused market research service

New tool to help reduce cost and time factors for colonoscopies

Clinical Genomics extends collaboration with CSIRO

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Fred Hutchinson Cancer Research Center receives 60 research grants totaling nearly $40.4 million

Scientists identify new interference method to target cancer cells

Group Health Research Institute to receive federal stimulus funds from ARRA

$16 million federal stimulus funds for cancer research projects

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

UnitedHealthcare launches 2010 portfolio of Medicare products

Diagnocure signs agreement with Lab21 for marketing its Previstage test

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

New strategic research service for the oncology market launched by Health Strategies Group

Screening and diagnostic tests contribute to health care value across spectrum of care

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

New center for gastrointestinal cancer research established

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Younger women with metastatic colorectal cancer live longer than younger men

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News